HKU Scholars Hub: Browsing DSpace

Browsing by Author Yiu, WH

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 41 to 59 of 59 < previous

	Title	Author(s)	Issue Date	Views
	Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy – Interim analysis of an add-on, randomised, controlled, multi-centre, open-label pragmatic trial Proceeding/Conference:International Congress of Chinese nephrologists	Chan, KW Kwong, ASK Lui, SL Ip, TP Chan, GCW Cowling, BJ Yiu, WH Wong, WLD LI, B LI, Y Feng, Y Tan, KCB Chan, YY Leung, JCK Lai, KN Tang, SCW	2017	106
	Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy – Preliminary results of an add-on, randomised, controlled, multi-centre, open-label pragmatic trial Proceeding/Conference:Journal of the American Society of Nephrology	Chan, KW Kwong, ASK Lui, SL Ip, TP Chan, GCW Cowling, BJ Yiu, WH Wong, WLD Li, B Li, Y Feng, Y Tan, KCB Chan, YY Leung, JCK Lai, KN Tang, SCW	2017	101
	Semi-individualised Chinese medicine treatment as an adjuvant management for diabetic nephropathy: a pilot add-on, randomised, controlled, multicentre, open-label pragmatic clinical trial Journal:BMJ Open	Chan, KW Ip, TP Kwong, ASK Lui, SL Chan, GCW Cowling, BJ Yiu, WH Wong, DWL Liu, Y Feng, Y Tan, KCB Chan, LYY Leung, JCK Lai, KN Tang, SCW	2016	69
	Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy: Interim analysis of an add-on, randomised, controlled, multi-centre, open-label pragmatic trial Proceeding/Conference:Hong Kong Medical Journal	Chan, KW Kwong, ASK Lui, SL Ip, TP Chan, GCW Cowling, BJ Yiu, WH Wong, WLD Li, B Li, Y Feng, Y Tan, KCB Chan, YY Leung, JCK Lai, KN Tang, SCW	2018	94
	Semi-individualised Chinese medicine treatment for diabetic kidney disease - from users' perspectives to SCHEMATIC trial interim result and potential mechanism. Proceeding/Conference:Good Practice in Traditional Chinese Medicine Research Association, London.	Chan, KW Kwong, AS Chan, GC Leung, CP Yiu, WH Lui, SL Ip, TP Cowling, BJ Wong, DW Li, B Li, Y Feng, Y Chan, LY Leung, JCK Tan, KCB Wong, VC Lai, KN Tang, SCW	2017	60
	Semi-individualised Chinese Medicine Treatment for Diabetic Kidney Disease – From users’ perspectives to SCHEMATIC trial interim result and potential mechanisms Proceeding/Conference:Advances in Integrative Medicine	Chan, KW Kwong, ASK Chan, GCW Leung, CPS Yiu, WH Lui, SL Ip, TP Cowling, BJ Wong, WLD Li, B Li, Y Feng, Y Chan, YY Leung, JCK Tan, KCB Wong, CWV Lai, KN Tang, SCW	2019	123
	Spleen Tyrosine Kinase Inhibition Ameliorates Tubular Inflammation in IgA Nephropathy Journal:Frontiers in Physiology	Yiu, WH Chan, KW Chan, LYY Leung, JCK Lai, KN Tang, SCW	2021	10
	Spleen Tyrosine Kinase Inhibitor Ameliorates Tubular Inflammation in IgA Nephropathy. Proceeding/Conference:Journal of the American Society of Nephrology	Yiu, WH Wong, WLD Wu, H Chan, KW Liu, Y Chan, LYY Leung, JCK Lai, KN Tang, SCW	2016	30
	The Expectation, Concern, and Experience of patients towards Integrative Chinese-western Medicine for Diabetic Kidney Disease: A qualitative study Proceeding/Conference:Journal of the American Society of Nephrology	Chan, KW Leung, C Chan, GCW Yiu, WH Wong, WLD Li, B Li, Y Chan, YY Leung, JCK Tang, SCW	2017	45
	The PAR-1 antagonist Vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis Journal:Clinical Science	Lok, SWY Yiu, WH Li, H Xue, R Zou, Y Li, B Chan, KW Chan, LYY Leung, JCK Lai, KN Tang, SCW	2020	39
	The PAR-1 Antagonist Vorapaxar Protects Against AKI To CKD Transition Proceeding/Conference:Journal of the American Society of Nephrology	LOK, WY Yiu, WH Chan, LYY Leung, JCK Lai, KN Tang, SCW	2020	8
	Thrombin induces Epithelial-Mesenchymal Transition through the activation of PAR-1 in Tubular Epithelial Cells Proceeding/Conference:Journal of the American Society of Nephrology	Yiu, WH Wong, WLD Leung, JCK Chan, LYY Lai, KN Tang, SCW	2014	49
	Tissue kallikrein mediates pro-inflammatory pathways and activation of protease-activated receptor-4 in proximal tubular epithelial cells. Journal:PLoS ONE	Yiu, WH WONG, WLD Chan, YY Leung, JCK Chan, KW lan, HY Lai, KN Tang, SCW	2014	56
	Tissue kallikrein mediates pro-inflammatory pathways in proximal tubular epithelial cells Proceeding/Conference:Journal of the American Society of Nephrology	Yiu, WH Wong, DWL Leung, JCK Chan, LYY Lan, HY Lai, KN Tang, SCW	2013	34
	The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy Journal:Kidney International	Lin, MIAO Yiu, WH LI, R WU, H WONG, WLD Chan, YY Leung, JCK Lai, KN Tang, SCW	2013	36
	Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy Journal:Journal of the American Society of Nephrology	Lin, M Yiu, WH Wu, HJ Chan, LYY Leung, JCK Au, WS Chan, KW Lai, KN Tang, SCW	2012	195
	Toll-like receptor activation: from renal inflammation to fibrosis Journal:Kidney International Supplements	Yiu, WH LIN, M Tang, SCW	2014	35
	Transforming Growth Factor Beta 1 Drives a Switch in Connexin Mediated Cell-to-Cell Communication in Tubular Cells of the Diabetic Kidney Journal:Cellular Physiology and Biochemistry	Hill, C Price, GW Wall, MJ Kaufmann, TJ Tang, SCW Yiu, WH Squires, PE	2018	42
	Tubular β-Catenin Ameliorates AKI by Regulating Apoptosis and Necroptosis Proceeding/Conference:Journal of the American Society of Nephrology	LI, H Leung, JCK Chan, LYY LI, B Yiu, WH Lai, KN Tang, SCW	2020	8

Showing results 41 to 59 of 59 < previous